The 7 major eczema markets reached a value of US$ 16.8 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 37.1 Billion by 2034, exhibiting a growth rate (CAGR) of 9.20% during 2023-2034.
The eczema market has been comprehensively analyzed in this report titled "Eczema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Eczema, also known as dermatitis, is a common skin condition that causes inflammation and irritation of the skin. This disorder impairs the barrier function of the skin, which is essential for retaining moisture and safeguarding the body from environmental factors. It is a chronic condition that typically starts in childhood but can also affect adults. The most typical symptoms of eczema include red, itchy, dry, and scaly patches on the skin, which can occur on any part of the body. Individuals suffering from this ailment may also have skin swelling, a rash, bumps, and flaky, scaly, or crusty skin. The diagnosis of the disease is typically made by a review of the patient's clinical features, medical history, and physical exam. The healthcare provider may also perform allergy and blood tests to evaluate the possible causes of the underlying indications. In some cases, a skin biopsy is further required, which involves the removal of a small sample of skin for medical examination.
The increasing prevalence of autoimmune disorders that can cause overstimulation of the body's defense system against environmental irritants or allergens is primarily driving the eczema market. Moreover, the rising incidences of various associated risk factors, such as exposure to air pollutants, certain skin care products, genetic mutation, stress, etc., are also bolstering the market growth. Besides this, the escalating utilization of effective medications, like anti-inflammatory drugs, antihistamines, corticosteroids, etc., to reduce itchiness and swelling in patients is acting as another significant growth-inducing factor. Additionally, the widespread adoption of light therapy, which uses ultraviolet (UV) light to treat the symptoms of eczema by suppressing overactive immune system cells that are responsible for inflammation, is also propelling the market growth. Furthermore, the inflating application of non-pharmacotherapy, like acupuncture, aromatherapy, lifestyle modification, etc., which can improve treatment outcomes in patients, is creating a positive outlook for the market. Apart from this, the emerging popularity of monoclonal antibodies, including rocatinlimab, for moderate to severe disease conditions, since they can enhance safety and lower toxicity among the population, is expected to drive the eczema market during the forecast period.
This report provides an exhaustive analysis of the eczema market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for eczema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the eczema market in any manner.
The eczema market has been comprehensively analyzed in this report titled "Eczema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Eczema, also known as dermatitis, is a common skin condition that causes inflammation and irritation of the skin. This disorder impairs the barrier function of the skin, which is essential for retaining moisture and safeguarding the body from environmental factors. It is a chronic condition that typically starts in childhood but can also affect adults. The most typical symptoms of eczema include red, itchy, dry, and scaly patches on the skin, which can occur on any part of the body. Individuals suffering from this ailment may also have skin swelling, a rash, bumps, and flaky, scaly, or crusty skin. The diagnosis of the disease is typically made by a review of the patient's clinical features, medical history, and physical exam. The healthcare provider may also perform allergy and blood tests to evaluate the possible causes of the underlying indications. In some cases, a skin biopsy is further required, which involves the removal of a small sample of skin for medical examination.
The increasing prevalence of autoimmune disorders that can cause overstimulation of the body's defense system against environmental irritants or allergens is primarily driving the eczema market. Moreover, the rising incidences of various associated risk factors, such as exposure to air pollutants, certain skin care products, genetic mutation, stress, etc., are also bolstering the market growth. Besides this, the escalating utilization of effective medications, like anti-inflammatory drugs, antihistamines, corticosteroids, etc., to reduce itchiness and swelling in patients is acting as another significant growth-inducing factor. Additionally, the widespread adoption of light therapy, which uses ultraviolet (UV) light to treat the symptoms of eczema by suppressing overactive immune system cells that are responsible for inflammation, is also propelling the market growth. Furthermore, the inflating application of non-pharmacotherapy, like acupuncture, aromatherapy, lifestyle modification, etc., which can improve treatment outcomes in patients, is creating a positive outlook for the market. Apart from this, the emerging popularity of monoclonal antibodies, including rocatinlimab, for moderate to severe disease conditions, since they can enhance safety and lower toxicity among the population, is expected to drive the eczema market during the forecast period.
This report provides an exhaustive analysis of the eczema market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for eczema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the eczema market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2032
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the eczema market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the eczema market
Competitive Landscape:
This report also provides a detailed analysis of the current eczema marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the eczema market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the eczema market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the eczema market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of eczema across the seven major markets?
- What is the number of prevalent cases (2018-2034) of eczema by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of eczema by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with eczema across the seven major markets?
- What is the size of the eczema patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of eczema?
- What will be the growth rate of patients across the seven major markets?
Eczema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for eczema drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the eczema market?
- What are the key regulatory events related to the eczema market?
- What is the structure of clinical trial landscape by status related to the eczema market?
- What is the structure of clinical trial landscape by phase related to the eczema market?
- What is the structure of clinical trial landscape by route of administration related to the eczema market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Eczema - Unmet Needs10 Eczema - Key Endpoints of Treatment13. Eczema - Attribute Analysis of Key Marketed and Pipeline Drugs16 Eczema - Recent Events and Inputs From Key Opinion Leaders18 Eczema Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Eczema - Introduction
5 Eczema - Disease Overview
7 Eczema - Epidemiology and Patient Population
8 Eczema - Treatment Algorithm, Guidelines, and Medical Practices
11 Eczema - Marketed Products
12 Eczema - Pipeline Drugs
14. Eczema - Clinical Trial Landscape
15 Eczema - Market Scenario
17 Eczema Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 16.8 Billion |
| Forecasted Market Value ( USD | $ 37.1 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
